{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:57Z","timestamp":1786120317887,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/dad.0b013e3181fe9746","type":"journal-article","created":{"date-parts":[[2011,10,29]],"date-time":"2011-10-29T08:56:30Z","timestamp":1319878590000},"page":"819-826","source":"Crossref","is-referenced-by-count":7,"title":["The Differential Diagnosis Between Primary Cutaneous Large B-cell Lymphoma and Cutaneous Follicular Lymphoma: Prognostic and Therapeutic Implications"],"prefix":"10.1097","volume":"33","author":[{"given":"Angel","family":"Fernandez-Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Smucler-Simonovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Manjon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-9-20210202","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.","volume":"143","author":"Senff","year":"2007","journal-title":"Arch Dermatol"},{"key":"R3-9-20210202","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.cco.0000239879.31463.42","article-title":"Primary cutaneous B-cell lymphoma: classification and treatment.","volume":"18","author":"Willemze","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"R4-9-20210202","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1046\/j.1365-2133.2001.04241.x","article-title":"Intralesional rituximab for cutaneous B-cell lymphoma.","volume":"144","author":"Paul","year":"2001","journal-title":"Br J Dermatol"},{"key":"R5-9-20210202","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2005.01.093","article-title":"Treatment of primary cutaneous B-cell lymphoma with rituximab.","volume":"52","author":"Fink-Puches","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R6-9-20210202","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.","volume":"155","author":"Kerl","year":"2006","journal-title":"Br J Dermatol"},{"key":"R7-9-20210202","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archdermatol.2009.23","article-title":"Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.","volume":"145","author":"Grange","year":"2009","journal-title":"Arch Dermatol"},{"key":"R8-9-20210202","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.0303-6987.2005.00495.x","article-title":"WHO\/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects.","volume":"32","author":"Burg","year":"2005","journal-title":"J Cutan Pathol"},{"key":"R9-9-20210202","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R10-9-20210202","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00000478-200107000-00005","article-title":"Cutaneous follicular B-cell lymphoma: description of a series of 18 cases.","volume":"25","author":"Franco","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"R11-9-20210202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R12-9-20210202","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/modpathol.2008.30","article-title":"Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma.","volume":"21","author":"Xie","year":"2008","journal-title":"Mod Pathol"},{"key":"R13-9-20210202","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/blood-2005-08-3443","article-title":"Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID.","volume":"107","author":"Dijkman","year":"2006","journal-title":"Blood"},{"key":"R14-9-20210202","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"R15-9-20210202","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"key":"R16-9-20210202","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H","article-title":"Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.","volume":"89","author":"Heinzerling","year":"2000","journal-title":"Cancer"},{"key":"R17-9-20210202","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0001-7310(08)74678-7","article-title":"Linfoma cutaneo de celulas B del centro folicular tratado con rituximab intralesional.","volume":"99","author":"Gamo","year":"2008","journal-title":"Actas Dermosifiliogr"},{"key":"R18-9-20210202","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0001-7310(05)73076-3","article-title":"Linfoma cutaneo de celulas grandes B de las piernas.","volume":"96","author":"Pedraz","year":"2005","journal-title":"Actas Dermosifiliogr"},{"key":"R19-9-20210202","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2133.2000.03607.x","article-title":"Rituximab in cutaneous B-cell lymphoma: a report of two cases.","volume":"143","author":"Sabroe","year":"2000","journal-title":"Br J Dermatol"},{"key":"R20-9-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00432-001-0313-2","article-title":"Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.","volume":"128","author":"Bonnekoh","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"R21-9-20210202","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.0007-0963.2001.04520.x","article-title":"Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer.","volume":"146","author":"Garbea","year":"2002","journal-title":"Br J Dermatol"},{"key":"R22-9-20210202","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0001-7310(08)74722-7","article-title":"Nodulos en las piernas.","volume":"99","author":"Cervigon","year":"2008","journal-title":"Actas Dermosifiliogr"},{"key":"R23-9-20210202","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2230.2004.01659.x","article-title":"Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.","volume":"30","author":"Lacouture","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"R24-9-20210202","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/S0190-9622(03)00855-7","article-title":"Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.","volume":"49","author":"Fierro","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R25-9-20210202","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/S0190-9622(03)00889-2","article-title":"Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series.","volume":"49","author":"Brogan","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R26-9-20210202","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/120347540300700606","article-title":"Intravascular lymphoma presenting as telangectasias: response to rituximab and combination chemotherapy.","volume":"7","author":"Weichert","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"R27-9-20210202","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00277-004-0897-0","article-title":"Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy.","volume":"83","author":"Takacs","year":"2004","journal-title":"Ann Hematol"},{"key":"R28-9-20210202","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1684\/ejd.2009.0688","article-title":"Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy.","volume":"19","author":"Posada Garcia","year":"2009","journal-title":"Eur J Dermatol"},{"key":"R29-9-20210202","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000421-200106000-00005","article-title":"Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).","volume":"24","author":"Aboulafia","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"R30-9-20210202","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1034\/j.1600-0560.2003.00078.x","article-title":"Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.","volume":"30","author":"Clarke","year":"2003","journal-title":"J Cutan Pathol"},{"key":"R31-9-20210202","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03019.x","article-title":"Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.","volume":"114","author":"Foran","year":"2001","journal-title":"Br J Haematol"},{"key":"R32-9-20210202","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","article-title":"Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkins lymphoma: a retrospective review.","volume":"119","author":"Kennedy","year":"2002","journal-title":"Br J Haematol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000372-201112000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:28:40Z","timestamp":1786048120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000372-201112000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0b013e3181fe9746","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}